 <h1>Ceftriaxone Side Effects</h1><ul class="ddc-anchor-links"><li>Consumer</li>
<li>Professional</li>
<li>FAQ</li></ul><h2 class="ddc-anchor-offset" id="consumer">For the Consumer</h2><p><i>Applies to ceftriaxone: injection powder for solution</i></p><h3>Side effects requiring immediate medical attention</h3><p>Along with its needed effects, ceftriaxone may cause some unwanted effects. Although not all of these side effects may occur, if they do occur they may need medical attention.</p><p>
<i>Check with your doctor or nurse immediately</i> if any of the following side effects occur while taking ceftriaxone:</p><p>
<i>More common</i>
</p><ul>
<li>Black, tarry stools</li>
<li>chest pain</li>
<li>chills</li>
<li>cough</li>
<li>fever</li>
<li>painful or difficult urination</li>
<li>shortness of breath</li>
<li>sore throat</li>
<li>sores, ulcers, or white spots on the lips or in the mouth</li>
<li>swollen glands</li>
<li>unusual bleeding or bruising</li>
<li>unusual tiredness or weakness</li>
</ul><p>
<i>Less common</i>
</p><ul>
<li>Diarrhea</li>
</ul><p>
<i>Rare</i>
</p><ul>
<li>Abdominal or stomach cramps or tenderness</li>
<li>back, leg, or stomach pains</li>
<li>bleeding gums</li>
<li>bloating</li>
<li>blood in the urine or stools</li>
<li>bloody nose</li>
<li>bluish color</li>
<li>changes in skin color</li>
<li>clay-colored stools</li>
<li>convulsions</li>
<li>cough or hoarseness</li>
<li>dark urine</li>
<li>diarrhea, watery and severe, which may also be bloody</li>
<li>difficulty with breathing</li>
<li>difficulty with swallowing</li>
<li>dizziness</li>
<li>fast, irregular, pounding, or racing heartbeat or pulse</li>
<li>feeling of discomfort</li>
<li>feeling of warmth</li>
<li>fever with or without chills</li>
<li>general body swelling</li>
<li>general feeling of tiredness or weakness</li>
<li>headache</li>
<li>hives</li>
<li>increased sweating</li>
<li>increased thirst</li>
<li>inflammation of the joints</li>
<li>itching</li>
<li>loss of appetite</li>
<li>lower back or side pain</li>
<li>muscle aches</li>
<li>nausea or vomiting</li>
<li>noisy breathing</li>
<li>nosebleeds</li>
<li>pain</li>
<li>pale skin</li>
<li>pinpoint red spots on the skin</li>
<li>puffiness or swelling of the eyelids or around the eyes, face, lips, or tongue</li>
<li>rash</li>
<li>redness of the face, neck, arms, and occasionally, upper chest</li>
<li>shortness of breath</li>
<li>skin rash</li>
<li>swelling of the foot or leg</li>
<li>swollen lymph glands</li>
<li>tenderness</li>
<li>tightness in the chest</li>
<li>troubled breathing with exertion</li>
<li>unpleasant breath odor</li>
<li>unusual weight loss</li>
<li>vomiting of blood</li>
<li>watery or bloody diarrhea</li>
<li>wheezing</li>
<li>yellowing of the eyes or skin</li>
</ul><p>
<i>Incidence not known</i>
</p><ul>
<li>Blistering, peeling, or loosening of the skin</li>
<li>chest pain</li>
<li>coughing up blood</li>
<li>decrease in the amount of urine</li>
<li>excessive muscle tone</li>
<li>increased menstrual flow or vaginal bleeding</li>
<li>muscle stiffness, tension, or tightness</li>
<li>nosebleeds</li>
<li>paralysis</li>
<li>prolonged bleeding from cuts</li>
<li>red irritated eyes</li>
<li>red or black, tarry stools</li>
<li>red or dark brown urine</li>
<li>red skin lesions, often with a purple center</li>
<li>restlessness</li>
<li>skin rash with a general disease</li>
<li>swelling</li>
<li>trouble sitting still</li>
<li>unpleasant breath odor</li>
</ul><h3>Side effects not requiring immediate medical attention</h3><p>Some side effects of ceftriaxone may occur that usually <b>do not need medical attention</b>. These side effects may go away during treatment as your body adjusts to the medicine. Also, your health care professional may be able to tell you about ways to prevent or reduce some of these side effects.</p><p>Check with your health care professional if any of the following side effects <b>continue or are bothersome</b> or if you have any questions about them:</p><p>
<i>Rare</i>
</p><ul>
<li>Acid or sour stomach</li>
<li>belching</li>
<li>bloated</li>
<li>change in taste</li>
<li>dizziness</li>
<li>excess air or gas in the stomach or intestines</li>
<li>full feeling</li>
<li>headache</li>
<li>heartburn</li>
<li>indigestion</li>
<li>itching of the vagina or genital area</li>
<li>loss of taste</li>
<li>pain during sexual intercourse</li>
<li>passing gas</li>
<li>stomach discomfort, upset, or pain</li>
<li>thick, white vaginal discharge with no odor or with a mild odor</li>
</ul><p>
<i>Incidence not known</i>
</p><ul>
<li>Hives or welts</li>
<li>redness, swelling, or soreness of the tongue</li>
<li>swelling or inflammation of the mouth</li>
</ul><p>
<!-- end injection powder for solution --><div class="related-links"><svg aria-hidden="true" class="ddc-icon ddc-icon-info" focusable="false" height="22" viewbox="0 0 24 24" width="22" xmlns="http://www.w3.org/2000/svg"><path d="M14 2H6c-1.1 0-1.99.9-1.99 2L4 20c0 1.1.89 2 1.99 2H18c1.1 0 2-.9 2-2V8l-6-6zm2 16H8v-2h8v2zm0-4H8v-2h8v2zm-3-5V3.5L18.5 9H13z"></path></svg> <span>Managing side effects <span class="ddc-text-nowrap">(general information)</span></span></div>
<h2 class="ddc-anchor-offset" id="professional">For Healthcare Professionals</h2><p><i>Applies to ceftriaxone: injectable powder for injection, intramuscular kit, intravenous powder for injection, intravenous solution</i></p><h3>General</h3><p>This drug was generally well tolerated.  The most common side effects were eosinophilia, leukopenia, thrombocytopenia, diarrhea, rash, and increased hepatic enzymes.  Incidence of side effects was somewhat higher in children and with higher doses.<sup>[Ref]</sup></p><h3>Local</h3><p><b>Very common</b> (10% or more): Warmth/tightness/induration with IM injection (up to 17%)</p>
<p><b>Uncommon</b> (0.1% to 1%): Injection site pain/discomfort, injection site induration, injection site tenderness, phlebitis after IV administration<sup>[Ref]</sup></p><p>Local side effects were increased if water was used as the diluent instead of lidocaine (lignocaine).</p>
<p></p>
<p>IM injection has been associated with warmth, tightness, and induration in 17% of patients receiving the 350 mg/mL solution and 5% of patients receiving the 250 mg/mL solution.<sup>[Ref]</sup></p><h3>Hematologic</h3><p>Nineteen cases (10 adults, 9 children) of immune hemolytic anemia have been reported, 9 of which were fatal.  Symptoms occurred within minutes or weeks of drug administration.  Initial symptoms included tachycardia, hypotension, dyspnea, pallor, back or leg pain, and decreased hemoglobin levels.  Most of these patients had preexisting hematologic or immunodeficiency disorders, and 1 had Crohn's disease.</p>
<p></p>
<p>Bleeding and bruising (due to hypoprothrombinemia) may have been more prevalent in patients with liver or renal dysfunction, malnourished patients, patients with low vitamin K levels, and patients using this drug for a prolonged duration.</p>
<p></p>
<p>Hemolytic anemia and agranulocytosis have also been reported during postmarketing experience.  Most cases of agranulocytosis (less than 500/mm3) were after 10 days of therapy and after total doses of at least 20 g.<sup>[Ref]</sup></p><p><b>Common</b> (1% to 10%): Eosinophilia, thrombocytosis, leukopenia, thrombocytopenia, neutropenia</p>
<p><b>Uncommon</b> (0.1% to 1%): Anemia, granulocytopenia, coagulopathy, hemolytic anemia, lymphopenia, prolonged prothrombin time</p>
<p><b>Rare</b> (less than 0.1%): Agranulocytosis, lymphocytosis, leukocytosis, monocytosis, basophilia, decreased prothrombin time, hemolysis (fatal)</p>
<p><b>Frequency not reported</b>: Bleeding, hypoprothrombinemia</p>
<p><b>Postmarketing reports</b>: Coombs' test false positive</p>
<p></p>
<p>Cephalosporin class:</p>
<p>-Frequency not reported: Aplastic anemia, hemorrhage, positive direct Coombs' test<sup>[Ref]</sup></p><h3>Hepatic</h3><p>Shadows on sonograms of the gallbladder (mistaken for gallstones, but actually ceftriaxone-calcium precipitates) have been reported, primarily after doses higher than the standard recommended dose.  Prospective studies showed variable incidence of precipitation with IV administration in children (more than 30% in some studies), but slow infusion (20 to 30 minutes) appeared to lower the incidence.  Risk of forming precipitates was increased by duration of therapy exceeding 14 days, renal failure, dehydration, or total parenteral nutrition.  Effect was usually asymptomatic, but clinical symptoms (e.g., pain, nausea, vomiting) have been reported.  Precipitation was usually reversible upon drug discontinuation.</p>
<p></p>
<p>Both pseudocholelithiasis (biliary "sludging") and true cholelithiasis (ceftriaxone-containing gallstone) have been reported in association with doses greater than 2 g/day.  A false-positive hepatobiliary scan occurred in a patient receiving this drug.  A repeat test 2 weeks after this drug was discontinued was normal.</p>
<p></p>
<p>Hepatitis has also been reported during postmarketing experience.<sup>[Ref]</sup></p><p><b>Common</b> (1% to 10%): Increased hepatic enzymes, increased ALT, increased AST</p>
<p><b>Uncommon</b> (0.1% to 1%): Increased bilirubin</p>
<p><b>Rare</b> (less than 0.1%): Hepatitis, jaundice, gallbladder sludge, biliary lithiasis, cholestatic jaundice</p>
<p><b>Frequency not reported</b>: Transient elevations in liver function tests, shadows on sonograms of the gallbladder, cholelithiasis, pseudocholelithiasis, false-positive hepatobiliary scan</p>
<p><b>Postmarketing reports</b>: Gallbladder precipitation</p>
<p></p>
<p>Cephalosporin class:</p>
<p>-Frequency not reported: Hepatic dysfunction, cholestasis<sup>[Ref]</sup></p><h3>Gastrointestinal</h3><p>The onset of pseudomembranous colitis symptoms has been reported during or after antimicrobial treatment.<sup>[Ref]</sup></p><p><b>Common</b> (1% to 10%): Diarrhea/loose stools</p>
<p><b>Uncommon</b> (0.1% to 1%): Nausea, vomiting</p>
<p><b>Rare</b> (less than 0.1%): Colitis, flatulence, dyspepsia, abdominal pain, pseudomembranous colitis</p>
<p><b>Frequency not reported</b>: Clostridium difficile-associated diarrhea</p>
<p><b>Postmarketing reports</b>: Pancreatitis, stomatitis, glossitis<sup>[Ref]</sup></p><h3>Dermatologic</h3><p><b>Common</b> (1% to 10%): Rash</p>
<p><b>Uncommon</b> (0.1% to 1%): Pruritus, maculopapular rash/exanthema, allergic dermatitis, diaphoresis</p>
<p><b>Rare</b> (less than 0.1%): Urticaria</p>
<p><b>Frequency not reported</b>: Severe dermatitis, exfoliative erythroderma, bruising</p>
<p><b>Postmarketing reports</b>: Exanthema, severe cutaneous reactions, erythema multiforme, Stevens-Johnson syndrome, Lyell's syndrome/toxic epidermal necrolysis, acute generalized exanthematous pustulosis (AGEP)</p>
<p></p>
<p>Cephalosporin class:</p>
<p>-Frequency not reported: Contact dermatitis<sup>[Ref]</sup></p><p>A case of AGEP has been reported after administration of this drug.  This was characterized by the appearance of an erythematous and generalized scarlatiniform rash with plaques covered by small nonfollicular pustules on the thighs, abdomen, and lower extremities.  This drug was discontinued and the AGEP was completely resolved after 2 weeks.</p>
<p></p>
<p>Allergic dermatitis and urticaria have also been reported during postmarketing experience.</p>
<p></p>
<p>A case of occupational contact dermatitis has been reported in a nurse who prepared cephalosporin solutions for administration to patients.  The dermatitis resolved after the nurse stopped preparing the solutions.<sup>[Ref]</sup></p><h3>Renal</h3><p><b>Common</b> (1% to 10%): Increased BUN/serum urea</p>
<p><b>Uncommon</b> (0.1% to 1%): Increased blood creatinine</p>
<p><b>Rare</b> (less than 0.1%): Renal precipitations, nephrolithiasis, acute renal tubular necrosis</p>
<p><b>Postmarketing reports</b>: Oliguria, ureteric obstruction, post-renal acute renal failure</p>
<p></p>
<p>Cephalosporin class:</p>
<p>-Frequency not reported: Renal dysfunction, toxic nephropathy<sup>[Ref]</sup></p><p>Cases of renal precipitation have been reported, primarily in children older than 3 years who received either high daily doses (e.g., at least 80 mg/kg/day) or total doses exceeding 10 g and who had other risk factors (e.g., fluid restrictions, confinement to bed).  Risk of forming precipitates was increased in immobilized or dehydrated patients.  Precipitation was reversible upon drug discontinuation.</p>
<p></p>
<p>Renal precipitation has also been reported during postmarketing experience.<sup>[Ref]</sup></p><h3>Genitourinary</h3><p><b>Uncommon</b> (0.1% to 1%): Genital fungal infection, urinary casts, candidiasis, vaginitis</p>
<p><b>Rare</b> (less than 0.1%): Glycosuria, hematuria, crystalluria<sup>[Ref]</sup></p><h3>Other</h3><p>Severe and sometimes fatal reactions have been reported in term and premature newborns (younger than 28 days) treated with IV ceftriaxone and calcium-containing IV solutions; a crystalline material (ceftriaxone-calcium precipitate) has been observed in the lungs and kidneys at autopsy.  The same IV infusion line was used for this drug and calcium-containing solutions in some cases; precipitate was observed in the IV infusion line in some cases.  Ceftriaxone and calcium-containing solutions infused at different times by different IV lines resulted in at least 1 neonate fatality; there was no crystalline material observed at autopsy.</p>
<p></p>
<p>Edema has also been reported during postmarketing experience.<sup>[Ref]</sup></p><p><b>Uncommon</b> (0.1% to 1%): Pyrexia/fever, flushing</p>
<p><b>Rare</b> (less than 0.1%): Edema, chills, drug fever, shivering</p>
<p><b>Postmarketing reports</b>: Superinfection with nonsusceptible microorganisms, ceftriaxone-calcium precipitates/crystalline material</p>
<p></p>
<p>Cephalosporin class:</p>
<p>-Frequency not reported: Drug fever, superinfection<sup>[Ref]</sup></p><h3>Nervous system</h3><p><b>Uncommon</b> (0.1% to 1%): Headache, dizziness, dysgeusia</p>
<p><b>Rare</b> (less than 0.1%): Seizures</p>
<p><b>Postmarketing reports</b>: Convulsion, vertigo, kernicterus</p>
<p></p>
<p>Cephalosporin class:</p>
<p>-Frequency not reported: Reversible hyperactivity, hypertonia, seizures triggered<sup>[Ref]</sup></p><p>Several cephalosporins have been implicated in triggering seizures, especially in patients with renal dysfunction when dose was not reduced.<sup>[Ref]</sup></p><h3>Metabolic</h3><p><b>Uncommon</b> (0.1% to 1%): Increased alkaline phosphatase</p>
<p><b>Postmarketing reports</b>: Galactosemia test false positive, false-positive test for urinary glucose (nonenzymatic methods)</p>
<p></p>
<p>Cephalosporin class:</p>
<p>-Frequency not reported: Increased LDH, false-positive test for urinary glucose<sup>[Ref]</sup></p><h3>Hypersensitivity</h3><p><b>Rare</b> (less than 0.1%): Anaphylaxis/anaphylactic-type reactions (e.g., bronchospasms), serum sickness</p>
<p><b>Frequency not reported</b>: Allergic reaction, cross-sensitivity</p>
<p><b>Postmarketing reports</b>: Anaphylaxis (anaphylactic shock, transient leukopenia, neutropenia, agranulocytosis, thrombocytopenia), anaphylactic reaction, anaphylactoid reaction, hypersensitivity</p>
<p></p>
<p>Cephalosporin class:</p>
<p>-Frequency not reported: Allergic reactions, serum sickness-like reaction<sup>[Ref]</sup></p><p>An allergic reaction manifested by itching, maculopapular rash, hyperthermia, flushing has been reported in a patient with X-linked agammaglobulinemia in the absence of IgE.  T cell involvement was proposed as the mechanism.</p>
<p></p>
<p>Cross-sensitivity with other cephalosporins and penicillins has occurred; however, the incidence is unknown.<sup>[Ref]</sup></p><h3>Cardiovascular</h3><p><b>Rare</b> (less than 0.1%): Palpitations</p>
<p><b>Frequency not reported</b>: Thrombus<sup>[Ref]</sup></p><h3>Respiratory</h3><p><b>Rare</b> (less than 0.1%): Bronchospasm, epistaxis, allergic pneumonitis<sup>[Ref]</sup></p><div class="referenceList"><h4 id="refs">References</h4><p id="ref_1">1. Cerner Multum,  Inc. "Australian Product Information." O 0</p><p id="ref_2">2. Cerner Multum,  Inc. "UK Summary of Product Characteristics." O 0</p><p id="ref_3">3. "Product Information. Rocephin (ceftriaxone)." Roche Laboratories, Nutley, NJ. </p><p id="ref_4">4. Dattwyler RJ, Luft BJ, Kunkel MJ, Finkel MF, Wormser GP, Rush TJ, Grunwaldt E, Agger WA, Franklin M, Oswald D, Cockey L, Maladorno D "Ceftriaxone compared with doxycycline for the treatment of acute disseminated Lyme disease." N Engl J Med 337 (1997): 289-94</p><p id="ref_5">5. Hayward CJ, Nafziger AN, Kohlhepp SJ, Bertino JS "Investigation of bioequivalence and tolerability of intramuscular ceftriaxone injections by using 1% lidocaine, buffered lidocaine, and sterile water diluents." Antimicrob Agents Chemother 40 (1996): 485-7</p><p id="ref_6">6. Pletz MW,  Rau M,  Bulitta J, et al. "Ertapenem pharmacokinetics and impact on intestinal microflora, in comparison to those of ceftriaxone, after multiple dosing in male and female volunteers." Antimicrob Agents Chemother 48 (2004): 3765-72</p><p id="ref_7">7. Nahata MC, Barson WJ "Ceftriaxone: a third-generation cephalosporin." Drug Intell Clin Pharm 19 (1985): 900-6</p><p id="ref_8">8. Rey D, Martin T, Albert A, Pasquali JL "Ceftriaxone-induced granulopenia related to a peculiar mechanism of granulopoiesis inhibition." Am J Med 87 (1989): 591-2</p><p id="ref_9">9. Duncan CJ,  Evans TJ,  Seaton RA "Ceftriaxone-related agranulocytosis during outpatient parenteral antibiotic therapy." J Antimicrob Chemother 65 (2010): 2483-4</p><p id="ref_10">10. Fallon BA,  Keilp JG,  Corbera KM, et al. "A randomized, placebo-controlled trial of repeated IV antibiotic therapy for Lyme encephalopathy." Neurology  (2007):</p><p id="ref_11">11. Nadelman RB, Arlin Z, Wormser GP "Life-threatening complications of empiric ceftriaxone therapy for seronegative Lyme disease." South Med J 84 (1991): 1263-5</p><p id="ref_12">12. Baciewicz AM, Skiest DJ, Weinshel EL "Ceftriaxone-associated neutropenia." Drug Intell Clin Pharm 22 (1988): 826-7</p><p id="ref_13">13. Valesova H, Mailer J, Havlik J, Hulinska D, Hercogova J "Long-term results in patients with Lyme arthritis following treatment with ceftriaxone." Infection 24 (1996): 98-102</p><p id="ref_14">14. Hull RL, Brandon D "Thrombocytopenia possibly caused by structurally related third-generation cephalosporins." Ann Pharmacother 25 (1991): 135-6</p><p id="ref_15">15. Valesova M, Mailer H, Havlik J, Hulinska D, Hercogova J "Long-term results in patients with lyme arthritis following treatment with ceftriaxone." Infection 24 (1996): 98-102</p><p id="ref_16">16. "Hemolysis from Ceftriaxone." Med Lett Drugs Ther 44 (2002): 100-101</p><p id="ref_17">17. Ramakrishnan K,  Scheid DC "Diagnosis and management of acute pyelonephritis in adults." Am Fam Physician 71 (2005): 933-42</p><p id="ref_18">18. Bickford CL,  Spencer AP "Biliary sludge and hyperbilirubinemia associated with ceftriaxone in an adult: case report and review of the literature." Pharmacotherapy 25 (2005): 1389-95</p><p id="ref_19">19. Rivkin AM "Hepatocellular enzyme elevations in a patient receiving ceftriaxone." Am J Health Syst Pharm 62 (2005): 2006-2010</p><p id="ref_20">20. Eichmann A, Weidmann G, Havas L "One-dose treatment of acute uncomplicated gonorrhoea of male patients with ceftriaxone Ro 13-9904, a new parenteral cephalosporin: a dose-range finding pilot study." Chemotherapy 27 (1981): 62-9</p><p id="ref_21">21. Simon N,  Dussol B,  Sampol E, et al. "Population pharmacokinetics of ceftriaxone and pharmacodynamic considerations in haemodialysed patients." Clin Pharmacokinet 45 (2006): 493-501</p><p id="ref_22">22. Zinberg J, Chernaik R, Coman E, Rosenblatt R, brandt LJ "Reversible symptomatic biliary obstruction associated with ceftriaxone pseudolithiasis." Am J Gastroenterol 86 (1991): 1251-4</p><p id="ref_23">23. Pigrau C, Pahissa A, Gropper S, Sureda D, Martinez Vazquez JM "Ceftriaxone-associated biliary pseudolithiasis in adults." Lancet 2 (1989): 165</p><p id="ref_24">24. Rohacova H, Hancil J, Hulinska D, Mailer H, Havlik J "Ceftriaxone in the treatment of lyme neuroborreliosis." Infection 24 (1996): 88-90</p><p id="ref_25">25. Arredondo JL, Diaz V, Gaitan H, Maradiegue E, Oyarzun E, Paz R, Reynal JL, Stamm W, Zambrano D "Oral clindamycin and ciprofloxacin versus intramuscular ceftriaxone and oral doxycycline in the treatment of mild-to-moderate pelvic inflammatory disease in outpatients." Clin Infect Dis 24 (1997): 170-8</p><p id="ref_26">26. Maranan MC, Gerber SI, Miller GG "Gallstone pancreatitis caused by ceftriaxone." Pediat Inf Dis J 17 (1998): 662-3</p><p id="ref_27">27. Bailey RR, Walker RJ, Cook HB "Ceftriaxone-induced colitis." N Z Med J 98 (1985): 969</p><p id="ref_28">28. Wormser GP "Clinical practice. Early Lyme disease." N Engl J Med 354 (2006): 2794-801</p><p id="ref_29">29. Meyboom RH, Kuiper H, Jansen A "Ceftriaxone and reversible cholelithiasis." BMJ 297 (1988): 858</p><p id="ref_30">30. Kirejczyk WM, Crowe HM, Mackay IM, Quintiliani R, Cronin EB "Disappearing "gallstones": biliary pseudolithiasis complicating ceftriaxone therapy." Am J Roentgenol 159 (1992): 329-30</p><p id="ref_31">31. Moskovitz, BL "Clinical adverse effects during ceftriaxone therapy." Am J Med 77 (1984): 84-8</p><p id="ref_32">32. Thomas P, Daly S, Misan G, Steele T "Comparison of the efficacy and adverse effect profile of cefotaxime and ceftriaxone in ICU patients with susceptible infections." Diagn Microbiol Infect Dis 15 (1992): 89-97</p><p id="ref_33">33. Lopez AJ, O'Keefe P, Morrissey M, Pickleman J "Ceftriaxone-induced cholelithiasis." Ann Intern Med 115 (1991): 712-4</p><p id="ref_34">34. Toll LL, Lee M, Sharifi R "Cefoxitin-induced interstitial nephritis." South Med J 80 (1987): 274-5</p><p id="ref_35">35. Gargollo PC,  Barnewolt CE,  Diamond DA "PEDIATRIC CEFTRIAXONE NEPHROLITHIASIS." J Urol 173 (2005): 577-578</p><p id="ref_36">36. Haskell RJ, Fujita NK, Stevenson JA, Border WA "Cefoxitin-induced interstitial nephritis." Arch Intern Med 141 (1981): 1557</p><p id="ref_37">37. Grasberger H, Otto B, Loeschke K "Ceftriaxone-associated nephrolithiasis." Ann Pharmacother 34 (2000): 1076-7</p><p id="ref_38">38. Thiella G, Bucci L, Agrati AM, Palmieri G "Nonfatal anaphylactic shock following an unusual sensitization." J Occup Med 31 (1989): 490</p><p id="ref_39">39. Romano A, Mayorga C, Torres MJ, Artesani MC, Suau R, Sanchez F, Perez E, Venuti A, Blanca M "Immediate allergic reactions to cephalosporins: Cross-reactivity and selective responses." J Allerg Clin Immunol 106 (2000): 1177-83</p><p id="ref_40">40. Baniasadi S,  Fahimi F,  Mansouri D "Serum sickness-like reaction associated with cefuroxime and ceftriaxone." Ann Pharmacother 41 (2007):</p><p id="ref_41">41. Moallem HJ, Garratty G, Wakeham M, Dial S, Oligario A, Gondi A, Rao SP, Fikrig S "Ceftriaxone-related fatal hemolysis in an adolescent with perinatally acquired human immunodeficiency virus infection." J Pediatr 133 (1998): 279-81</p><p id="ref_42">42. Filipe P, Almeida RSLS, Rodrigo FG "Occupational allergic contact dermatitis from cephalosporins." Contact Dermatitis 34 (1996): 226</p><p id="ref_43">43. Kudva-Patel V,  White E,  Karnani R,  Collins MH,  Assa'ad AH "Drug reaction to ceftriaxone in a child with X-linked agammaglobulinemia." J Allergy Clin Immunol 109(5 Pt 1) (2002): 888-9</p><p id="ref_44">44. Lewis JD "Liquid sucralfate in the management of aphthous ulcers." Am Fam Physician 64 (2001): 737</p></div>
<h2 class="ddc-anchor-offset" id="faq">Frequently asked questions</h2>
<ul>
<li>Pregnancy - is it safe to take ceftriaxone during pregnancy?</li>
</ul>
<div class="more-resources" id="moreResources">
<h2>More about ceftriaxone</h2>
<ul class="more-resources-list more-resources-list-general">
<li>During Pregnancy or 
Breastfeeding</li>
<li>Dosage Information</li>
<li>Drug Interactions</li>
<li>Compare Alternatives</li>
<li>Pricing &amp; Coupons</li>
<li>En Español</li>
<li>137 Reviews</li>
<li>Drug class: third generation cephalosporins</li>
<li>FDA Alerts (2)</li>
</ul>
<h3>Consumer resources</h3>
<ul class="more-resources-list more-resources-list-consumer">
<li>Patient Information</li>
<li>Ceftriaxone Injection &lt;span&gt;(Advanced Reading)&lt;/span&gt;</li>
</ul>
<dl class="more-resources-other-brands more-resources-other-brands-consumer"><dt>Other brands</dt><dd>Rocephin</dd></dl>
<h3>Professional resources</h3>
<ul class="more-resources-list more-resources-list-professional">
<li>Prescribing Information</li>
<li data-more-config-id="list-data-resources-professional">... +3 more</li>
</ul>
<h3>Related treatment guides</h3>
<ul class="more-resources-list more-resources-list-conditions">
<li>Bone infection</li>
<li>Bacterial Infection</li>
<li>Bacterial Endocarditis Prevention</li>
<li>Bacteremia</li>
<li data-more-config-id="list-data-resources-conditions">... +40 more</li>
</ul>
</div>
<h2>Further information</h2><p class="ddc-disclaimer">Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.</p>
<p>Some side effects may not be reported. You may report them to the FDA.</p>
<p class="ddc-disclaimer-link">Medical Disclaimer</p>
<script>
function showRefs(refs) {
	if (!document.querySelectorAll) {
		return;
	}

	var referenceIds = refs ? refs.split(',') : [];
	var referenceTitle = referenceIds.length
		 ? "References relevant to chosen section <span class='ddc-text-size-small font-weight-normal'>(<a href='#refs' onclick='showRefs(\"\"); return false;'>Show all references</a>)</span>"
		 : "References";
	document.getElementById('refs').innerHTML = referenceTitle;

	// Show/hide reference items
	var referenceList = document.querySelectorAll('.referenceList p');
	referenceList.forEach(function(item) {
		var id = item.id.replace('ref_', '');
		if (!referenceIds.length || referenceIds.includes(id)) {
			item.style.display = 'block';
		}
		else {
			item.style.display = 'none';
		}
	});
}
</script>
</p><h2 class="ddc-anchor-offset" id="professional">For Healthcare Professionals</h2><p><i>Applies to ceftriaxone: injectable powder for injection, intramuscular kit, intravenous powder for injection, intravenous solution</i></p><h3>General</h3><p>This drug was generally well tolerated.  The most common side effects were eosinophilia, leukopenia, thrombocytopenia, diarrhea, rash, and increased hepatic enzymes.  Incidence of side effects was somewhat higher in children and with higher doses.<sup>[Ref]</sup></p><h3>Local</h3><p><b>Very common</b> (10% or more): Warmth/tightness/induration with IM injection (up to 17%)</p><p><b>Uncommon</b> (0.1% to 1%): Injection site pain/discomfort, injection site induration, injection site tenderness, phlebitis after IV administration<sup>[Ref]</sup></p><p>Local side effects were increased if water was used as the diluent instead of lidocaine (lignocaine).</p><p></p><p>IM injection has been associated with warmth, tightness, and induration in 17% of patients receiving the 350 mg/mL solution and 5% of patients receiving the 250 mg/mL solution.<sup>[Ref]</sup></p><h3>Hematologic</h3><p>Nineteen cases (10 adults, 9 children) of immune hemolytic anemia have been reported, 9 of which were fatal.  Symptoms occurred within minutes or weeks of drug administration.  Initial symptoms included tachycardia, hypotension, dyspnea, pallor, back or leg pain, and decreased hemoglobin levels.  Most of these patients had preexisting hematologic or immunodeficiency disorders, and 1 had Crohn's disease.</p><p></p><p>Bleeding and bruising (due to hypoprothrombinemia) may have been more prevalent in patients with liver or renal dysfunction, malnourished patients, patients with low vitamin K levels, and patients using this drug for a prolonged duration.</p><p></p><p>Hemolytic anemia and agranulocytosis have also been reported during postmarketing experience.  Most cases of agranulocytosis (less than 500/mm3) were after 10 days of therapy and after total doses of at least 20 g.<sup>[Ref]</sup></p><p><b>Common</b> (1% to 10%): Eosinophilia, thrombocytosis, leukopenia, thrombocytopenia, neutropenia</p><p><b>Uncommon</b> (0.1% to 1%): Anemia, granulocytopenia, coagulopathy, hemolytic anemia, lymphopenia, prolonged prothrombin time</p><p><b>Rare</b> (less than 0.1%): Agranulocytosis, lymphocytosis, leukocytosis, monocytosis, basophilia, decreased prothrombin time, hemolysis (fatal)</p><p><b>Frequency not reported</b>: Bleeding, hypoprothrombinemia</p><p><b>Postmarketing reports</b>: Coombs' test false positive</p><p></p><p>Cephalosporin class:</p><p>-Frequency not reported: Aplastic anemia, hemorrhage, positive direct Coombs' test<sup>[Ref]</sup></p><h3>Hepatic</h3><p>Shadows on sonograms of the gallbladder (mistaken for gallstones, but actually ceftriaxone-calcium precipitates) have been reported, primarily after doses higher than the standard recommended dose.  Prospective studies showed variable incidence of precipitation with IV administration in children (more than 30% in some studies), but slow infusion (20 to 30 minutes) appeared to lower the incidence.  Risk of forming precipitates was increased by duration of therapy exceeding 14 days, renal failure, dehydration, or total parenteral nutrition.  Effect was usually asymptomatic, but clinical symptoms (e.g., pain, nausea, vomiting) have been reported.  Precipitation was usually reversible upon drug discontinuation.</p><p></p><p>Both pseudocholelithiasis (biliary "sludging") and true cholelithiasis (ceftriaxone-containing gallstone) have been reported in association with doses greater than 2 g/day.  A false-positive hepatobiliary scan occurred in a patient receiving this drug.  A repeat test 2 weeks after this drug was discontinued was normal.</p><p></p><p>Hepatitis has also been reported during postmarketing experience.<sup>[Ref]</sup></p><p><b>Common</b> (1% to 10%): Increased hepatic enzymes, increased ALT, increased AST</p><p><b>Uncommon</b> (0.1% to 1%): Increased bilirubin</p><p><b>Rare</b> (less than 0.1%): Hepatitis, jaundice, gallbladder sludge, biliary lithiasis, cholestatic jaundice</p><p><b>Frequency not reported</b>: Transient elevations in liver function tests, shadows on sonograms of the gallbladder, cholelithiasis, pseudocholelithiasis, false-positive hepatobiliary scan</p><p><b>Postmarketing reports</b>: Gallbladder precipitation</p><p></p><p>Cephalosporin class:</p><p>-Frequency not reported: Hepatic dysfunction, cholestasis<sup>[Ref]</sup></p><h3>Gastrointestinal</h3><p>The onset of pseudomembranous colitis symptoms has been reported during or after antimicrobial treatment.<sup>[Ref]</sup></p><p><b>Common</b> (1% to 10%): Diarrhea/loose stools</p><p><b>Uncommon</b> (0.1% to 1%): Nausea, vomiting</p><p><b>Rare</b> (less than 0.1%): Colitis, flatulence, dyspepsia, abdominal pain, pseudomembranous colitis</p><p><b>Frequency not reported</b>: Clostridium difficile-associated diarrhea</p><p><b>Postmarketing reports</b>: Pancreatitis, stomatitis, glossitis<sup>[Ref]</sup></p><h3>Dermatologic</h3><p><b>Common</b> (1% to 10%): Rash</p><p><b>Uncommon</b> (0.1% to 1%): Pruritus, maculopapular rash/exanthema, allergic dermatitis, diaphoresis</p><p><b>Rare</b> (less than 0.1%): Urticaria</p><p><b>Frequency not reported</b>: Severe dermatitis, exfoliative erythroderma, bruising</p><p><b>Postmarketing reports</b>: Exanthema, severe cutaneous reactions, erythema multiforme, Stevens-Johnson syndrome, Lyell's syndrome/toxic epidermal necrolysis, acute generalized exanthematous pustulosis (AGEP)</p><p></p><p>Cephalosporin class:</p><p>-Frequency not reported: Contact dermatitis<sup>[Ref]</sup></p><p>A case of AGEP has been reported after administration of this drug.  This was characterized by the appearance of an erythematous and generalized scarlatiniform rash with plaques covered by small nonfollicular pustules on the thighs, abdomen, and lower extremities.  This drug was discontinued and the AGEP was completely resolved after 2 weeks.</p><p></p><p>Allergic dermatitis and urticaria have also been reported during postmarketing experience.</p><p></p><p>A case of occupational contact dermatitis has been reported in a nurse who prepared cephalosporin solutions for administration to patients.  The dermatitis resolved after the nurse stopped preparing the solutions.<sup>[Ref]</sup></p><h3>Renal</h3><p><b>Common</b> (1% to 10%): Increased BUN/serum urea</p><p><b>Uncommon</b> (0.1% to 1%): Increased blood creatinine</p><p><b>Rare</b> (less than 0.1%): Renal precipitations, nephrolithiasis, acute renal tubular necrosis</p><p><b>Postmarketing reports</b>: Oliguria, ureteric obstruction, post-renal acute renal failure</p><p></p><p>Cephalosporin class:</p><p>-Frequency not reported: Renal dysfunction, toxic nephropathy<sup>[Ref]</sup></p><p>Cases of renal precipitation have been reported, primarily in children older than 3 years who received either high daily doses (e.g., at least 80 mg/kg/day) or total doses exceeding 10 g and who had other risk factors (e.g., fluid restrictions, confinement to bed).  Risk of forming precipitates was increased in immobilized or dehydrated patients.  Precipitation was reversible upon drug discontinuation.</p><p></p><p>Renal precipitation has also been reported during postmarketing experience.<sup>[Ref]</sup></p><h3>Genitourinary</h3><p><b>Uncommon</b> (0.1% to 1%): Genital fungal infection, urinary casts, candidiasis, vaginitis</p><p><b>Rare</b> (less than 0.1%): Glycosuria, hematuria, crystalluria<sup>[Ref]</sup></p><h3>Other</h3><p>Severe and sometimes fatal reactions have been reported in term and premature newborns (younger than 28 days) treated with IV ceftriaxone and calcium-containing IV solutions; a crystalline material (ceftriaxone-calcium precipitate) has been observed in the lungs and kidneys at autopsy.  The same IV infusion line was used for this drug and calcium-containing solutions in some cases; precipitate was observed in the IV infusion line in some cases.  Ceftriaxone and calcium-containing solutions infused at different times by different IV lines resulted in at least 1 neonate fatality; there was no crystalline material observed at autopsy.</p><p></p><p>Edema has also been reported during postmarketing experience.<sup>[Ref]</sup></p><p><b>Uncommon</b> (0.1% to 1%): Pyrexia/fever, flushing</p><p><b>Rare</b> (less than 0.1%): Edema, chills, drug fever, shivering</p><p><b>Postmarketing reports</b>: Superinfection with nonsusceptible microorganisms, ceftriaxone-calcium precipitates/crystalline material</p><p></p><p>Cephalosporin class:</p><p>-Frequency not reported: Drug fever, superinfection<sup>[Ref]</sup></p><h3>Nervous system</h3><p><b>Uncommon</b> (0.1% to 1%): Headache, dizziness, dysgeusia</p><p><b>Rare</b> (less than 0.1%): Seizures</p><p><b>Postmarketing reports</b>: Convulsion, vertigo, kernicterus</p><p></p><p>Cephalosporin class:</p><p>-Frequency not reported: Reversible hyperactivity, hypertonia, seizures triggered<sup>[Ref]</sup></p><p>Several cephalosporins have been implicated in triggering seizures, especially in patients with renal dysfunction when dose was not reduced.<sup>[Ref]</sup></p><h3>Metabolic</h3><p><b>Uncommon</b> (0.1% to 1%): Increased alkaline phosphatase</p><p><b>Postmarketing reports</b>: Galactosemia test false positive, false-positive test for urinary glucose (nonenzymatic methods)</p><p></p><p>Cephalosporin class:</p><p>-Frequency not reported: Increased LDH, false-positive test for urinary glucose<sup>[Ref]</sup></p><h3>Hypersensitivity</h3><p><b>Rare</b> (less than 0.1%): Anaphylaxis/anaphylactic-type reactions (e.g., bronchospasms), serum sickness</p><p><b>Frequency not reported</b>: Allergic reaction, cross-sensitivity</p><p><b>Postmarketing reports</b>: Anaphylaxis (anaphylactic shock, transient leukopenia, neutropenia, agranulocytosis, thrombocytopenia), anaphylactic reaction, anaphylactoid reaction, hypersensitivity</p><p></p><p>Cephalosporin class:</p><p>-Frequency not reported: Allergic reactions, serum sickness-like reaction<sup>[Ref]</sup></p><p>An allergic reaction manifested by itching, maculopapular rash, hyperthermia, flushing has been reported in a patient with X-linked agammaglobulinemia in the absence of IgE.  T cell involvement was proposed as the mechanism.</p><p></p><p>Cross-sensitivity with other cephalosporins and penicillins has occurred; however, the incidence is unknown.<sup>[Ref]</sup></p><h3>Cardiovascular</h3><p><b>Rare</b> (less than 0.1%): Palpitations</p><p><b>Frequency not reported</b>: Thrombus<sup>[Ref]</sup></p><h3>Respiratory</h3><p><b>Rare</b> (less than 0.1%): Bronchospasm, epistaxis, allergic pneumonitis<sup>[Ref]</sup></p><p id="ref_1">1. Cerner Multum,  Inc. "Australian Product Information." O 0</p><p id="ref_2">2. Cerner Multum,  Inc. "UK Summary of Product Characteristics." O 0</p><p id="ref_3">3. "Product Information. Rocephin (ceftriaxone)." Roche Laboratories, Nutley, NJ. </p><p id="ref_4">4. Dattwyler RJ, Luft BJ, Kunkel MJ, Finkel MF, Wormser GP, Rush TJ, Grunwaldt E, Agger WA, Franklin M, Oswald D, Cockey L, Maladorno D "Ceftriaxone compared with doxycycline for the treatment of acute disseminated Lyme disease." N Engl J Med 337 (1997): 289-94</p><p id="ref_5">5. Hayward CJ, Nafziger AN, Kohlhepp SJ, Bertino JS "Investigation of bioequivalence and tolerability of intramuscular ceftriaxone injections by using 1% lidocaine, buffered lidocaine, and sterile water diluents." Antimicrob Agents Chemother 40 (1996): 485-7</p><p id="ref_6">6. Pletz MW,  Rau M,  Bulitta J, et al. "Ertapenem pharmacokinetics and impact on intestinal microflora, in comparison to those of ceftriaxone, after multiple dosing in male and female volunteers." Antimicrob Agents Chemother 48 (2004): 3765-72</p><p id="ref_7">7. Nahata MC, Barson WJ "Ceftriaxone: a third-generation cephalosporin." Drug Intell Clin Pharm 19 (1985): 900-6</p><p id="ref_8">8. Rey D, Martin T, Albert A, Pasquali JL "Ceftriaxone-induced granulopenia related to a peculiar mechanism of granulopoiesis inhibition." Am J Med 87 (1989): 591-2</p><p id="ref_9">9. Duncan CJ,  Evans TJ,  Seaton RA "Ceftriaxone-related agranulocytosis during outpatient parenteral antibiotic therapy." J Antimicrob Chemother 65 (2010): 2483-4</p><p id="ref_10">10. Fallon BA,  Keilp JG,  Corbera KM, et al. "A randomized, placebo-controlled trial of repeated IV antibiotic therapy for Lyme encephalopathy." Neurology  (2007):</p><p id="ref_11">11. Nadelman RB, Arlin Z, Wormser GP "Life-threatening complications of empiric ceftriaxone therapy for seronegative Lyme disease." South Med J 84 (1991): 1263-5</p><p id="ref_12">12. Baciewicz AM, Skiest DJ, Weinshel EL "Ceftriaxone-associated neutropenia." Drug Intell Clin Pharm 22 (1988): 826-7</p><p id="ref_13">13. Valesova H, Mailer J, Havlik J, Hulinska D, Hercogova J "Long-term results in patients with Lyme arthritis following treatment with ceftriaxone." Infection 24 (1996): 98-102</p><p id="ref_14">14. Hull RL, Brandon D "Thrombocytopenia possibly caused by structurally related third-generation cephalosporins." Ann Pharmacother 25 (1991): 135-6</p><p id="ref_15">15. Valesova M, Mailer H, Havlik J, Hulinska D, Hercogova J "Long-term results in patients with lyme arthritis following treatment with ceftriaxone." Infection 24 (1996): 98-102</p><p id="ref_16">16. "Hemolysis from Ceftriaxone." Med Lett Drugs Ther 44 (2002): 100-101</p><p id="ref_17">17. Ramakrishnan K,  Scheid DC "Diagnosis and management of acute pyelonephritis in adults." Am Fam Physician 71 (2005): 933-42</p><p id="ref_18">18. Bickford CL,  Spencer AP "Biliary sludge and hyperbilirubinemia associated with ceftriaxone in an adult: case report and review of the literature." Pharmacotherapy 25 (2005): 1389-95</p><p id="ref_19">19. Rivkin AM "Hepatocellular enzyme elevations in a patient receiving ceftriaxone." Am J Health Syst Pharm 62 (2005): 2006-2010</p><p id="ref_20">20. Eichmann A, Weidmann G, Havas L "One-dose treatment of acute uncomplicated gonorrhoea of male patients with ceftriaxone Ro 13-9904, a new parenteral cephalosporin: a dose-range finding pilot study." Chemotherapy 27 (1981): 62-9</p><p id="ref_21">21. Simon N,  Dussol B,  Sampol E, et al. "Population pharmacokinetics of ceftriaxone and pharmacodynamic considerations in haemodialysed patients." Clin Pharmacokinet 45 (2006): 493-501</p><p id="ref_22">22. Zinberg J, Chernaik R, Coman E, Rosenblatt R, brandt LJ "Reversible symptomatic biliary obstruction associated with ceftriaxone pseudolithiasis." Am J Gastroenterol 86 (1991): 1251-4</p><p id="ref_23">23. Pigrau C, Pahissa A, Gropper S, Sureda D, Martinez Vazquez JM "Ceftriaxone-associated biliary pseudolithiasis in adults." Lancet 2 (1989): 165</p><p id="ref_24">24. Rohacova H, Hancil J, Hulinska D, Mailer H, Havlik J "Ceftriaxone in the treatment of lyme neuroborreliosis." Infection 24 (1996): 88-90</p><p id="ref_25">25. Arredondo JL, Diaz V, Gaitan H, Maradiegue E, Oyarzun E, Paz R, Reynal JL, Stamm W, Zambrano D "Oral clindamycin and ciprofloxacin versus intramuscular ceftriaxone and oral doxycycline in the treatment of mild-to-moderate pelvic inflammatory disease in outpatients." Clin Infect Dis 24 (1997): 170-8</p><p id="ref_26">26. Maranan MC, Gerber SI, Miller GG "Gallstone pancreatitis caused by ceftriaxone." Pediat Inf Dis J 17 (1998): 662-3</p><p id="ref_27">27. Bailey RR, Walker RJ, Cook HB "Ceftriaxone-induced colitis." N Z Med J 98 (1985): 969</p><p id="ref_28">28. Wormser GP "Clinical practice. Early Lyme disease." N Engl J Med 354 (2006): 2794-801</p><p id="ref_29">29. Meyboom RH, Kuiper H, Jansen A "Ceftriaxone and reversible cholelithiasis." BMJ 297 (1988): 858</p><p id="ref_30">30. Kirejczyk WM, Crowe HM, Mackay IM, Quintiliani R, Cronin EB "Disappearing "gallstones": biliary pseudolithiasis complicating ceftriaxone therapy." Am J Roentgenol 159 (1992): 329-30</p><p id="ref_31">31. Moskovitz, BL "Clinical adverse effects during ceftriaxone therapy." Am J Med 77 (1984): 84-8</p><p id="ref_32">32. Thomas P, Daly S, Misan G, Steele T "Comparison of the efficacy and adverse effect profile of cefotaxime and ceftriaxone in ICU patients with susceptible infections." Diagn Microbiol Infect Dis 15 (1992): 89-97</p><p id="ref_33">33. Lopez AJ, O'Keefe P, Morrissey M, Pickleman J "Ceftriaxone-induced cholelithiasis." Ann Intern Med 115 (1991): 712-4</p><p id="ref_34">34. Toll LL, Lee M, Sharifi R "Cefoxitin-induced interstitial nephritis." South Med J 80 (1987): 274-5</p><p id="ref_35">35. Gargollo PC,  Barnewolt CE,  Diamond DA "PEDIATRIC CEFTRIAXONE NEPHROLITHIASIS." J Urol 173 (2005): 577-578</p><p id="ref_36">36. Haskell RJ, Fujita NK, Stevenson JA, Border WA "Cefoxitin-induced interstitial nephritis." Arch Intern Med 141 (1981): 1557</p><p id="ref_37">37. Grasberger H, Otto B, Loeschke K "Ceftriaxone-associated nephrolithiasis." Ann Pharmacother 34 (2000): 1076-7</p><p id="ref_38">38. Thiella G, Bucci L, Agrati AM, Palmieri G "Nonfatal anaphylactic shock following an unusual sensitization." J Occup Med 31 (1989): 490</p><p id="ref_39">39. Romano A, Mayorga C, Torres MJ, Artesani MC, Suau R, Sanchez F, Perez E, Venuti A, Blanca M "Immediate allergic reactions to cephalosporins: Cross-reactivity and selective responses." J Allerg Clin Immunol 106 (2000): 1177-83</p><p id="ref_40">40. Baniasadi S,  Fahimi F,  Mansouri D "Serum sickness-like reaction associated with cefuroxime and ceftriaxone." Ann Pharmacother 41 (2007):</p><p id="ref_41">41. Moallem HJ, Garratty G, Wakeham M, Dial S, Oligario A, Gondi A, Rao SP, Fikrig S "Ceftriaxone-related fatal hemolysis in an adolescent with perinatally acquired human immunodeficiency virus infection." J Pediatr 133 (1998): 279-81</p><p id="ref_42">42. Filipe P, Almeida RSLS, Rodrigo FG "Occupational allergic contact dermatitis from cephalosporins." Contact Dermatitis 34 (1996): 226</p><p id="ref_43">43. Kudva-Patel V,  White E,  Karnani R,  Collins MH,  Assa'ad AH "Drug reaction to ceftriaxone in a child with X-linked agammaglobulinemia." J Allergy Clin Immunol 109(5 Pt 1) (2002): 888-9</p><p id="ref_44">44. Lewis JD "Liquid sucralfate in the management of aphthous ulcers." Am Fam Physician 64 (2001): 737</p><h2 class="ddc-anchor-offset" id="faq">Frequently asked questions</h2><ul>
<li>Pregnancy - is it safe to take ceftriaxone during pregnancy?</li>
</ul><h2>More about ceftriaxone</h2><ul class="more-resources-list more-resources-list-general">
<li>During Pregnancy or 
Breastfeeding</li>
<li>Dosage Information</li>
<li>Drug Interactions</li>
<li>Compare Alternatives</li>
<li>Pricing &amp; Coupons</li>
<li>En Español</li>
<li>137 Reviews</li>
<li>Drug class: third generation cephalosporins</li>
<li>FDA Alerts (2)</li>
</ul><h3>Consumer resources</h3><ul class="more-resources-list more-resources-list-consumer">
<li>Patient Information</li>
<li>Ceftriaxone Injection &lt;span&gt;(Advanced Reading)&lt;/span&gt;</li>
</ul><h3>Professional resources</h3><ul class="more-resources-list more-resources-list-professional">
<li>Prescribing Information</li>
<li data-more-config-id="list-data-resources-professional">... +3 more</li>
</ul><h3>Related treatment guides</h3><ul class="more-resources-list more-resources-list-conditions">
<li>Bone infection</li>
<li>Bacterial Infection</li>
<li>Bacterial Endocarditis Prevention</li>
<li>Bacteremia</li>
<li data-more-config-id="list-data-resources-conditions">... +40 more</li>
</ul><h2>Further information</h2><p class="ddc-disclaimer">Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.</p><p>Some side effects may not be reported. You may report them to the FDA.</p><p class="ddc-disclaimer-link">Medical Disclaimer</p>